OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases


10-12 September 2017
Rodman & Renshaw – 19th Annual Global Investment Conference, New York

4-5 October 2017
European Large & Midcap Event, Paris

19 October 2017
Seminaire Biotech Portzamparc, Paris

OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies which act on effector and suppressor cells to stimulate or inhibit the body’s immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. These new generation products are optimized to better target key receptors of the immune response’s activation or regulation, thus allowing for longer therapeutic effects.

The company has a portfolio of advanced immunotherapy products in clinical phases 2 and 3, of promising products in preclinical phase and of potential drug candidates in R&D. This product portoflio is supported by an innovative technology platform and know-how in selection and optimization of receptor targeting, enabling thus significant therapeutic achievements.